Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase I, Open-label, Dose-escalation Study of the Safety and Pharmacokinetics of IMP4297 in Patients With Advanced Solid Tumors

NCT03508011 is registered in ClinicalTrials.gov with Impact Therapeutics, Inc. as lead sponsor.

NCT NCT03508011
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT03508011 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase I, Open-label, Dose-escalation Study of the Safety and Pharmacokinetics of IMP4297 in Patients With Advanced Solid Tumors
Lead sponsor
Impact Therapeutics, Inc.
Phase
Phase 1
Overall status
Completed
Start date
August 23, 2017
Completion date
December 16, 2020
Enrollment
57 (actual)
Sites
2

Conditions

As the registry lists them; a condition with its own page is linked.

advanced solid tumours, breast cancer, ovarian cancer, prostate cancer